2022 04 13 patent update

CS MEDICA provides patent update

CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has completed one national and two PCT continuation patents, out of the in total 7 patents applications covering 11 products.

CS MEDICA strives toward granting patent acceptance on all present and future treatment products. All CS MEDICA’s treatment products (topical and oral products) as of today are patented in accordance with PCT (Patent Cooperation Treaty), covering 153 nations across the globe. The Company currently has seven proceeding patents that are filed and pending.

The three completed applications are continuations of the patent application earlier submitted. The three continuations applications includes:

  • One national continuation of PCT Patent application PA 2019 70497 (phase III), Topical Formulations Comprising Cannabidiol, Method of Preparing the Composition and use thereof, has been completed in Australia, Canada, China, Europe, Israel, India, Japan, South Korea, New Zealand and the USA.
  • one PCT continuation of the Danish patent application of PA 2021 70056 (phase II), Supplement For Arthritis and Psoriasis, has been completed.
  • one PCT continuation of the Danish patent application of PA 2021 70171(Phase II), Hair Serum and Supplement, has been completed.

Where the patent applications phases includes the following;

  • Phase I: DK application
  • Phase II: continuations of the DK application to the PCT application, covering 153 nations across the globe
  • Phase III: continuations of the PCT application to national applications

The above-mentioned continuations of patent application cover Arthritis Gel, Psoriasis Gel, Arthritis Oral, Psoriasis Oral, Anti-hair loss serum and Anti-hair loss oral.

The patents are intended to strengthen the protection of the Company’s products. If granted, the patents will protect the technology til 2039 (patent filed in 2019) and 2041 (patents filed in 2021).

After the PCT (phase II), the patents will enter national phases (phase III) where CS MEDICA needs to determine in which countries and/or regions the Company intend to pursue patents. It is the current strategy to extend this protection worldwide, such as in the US, China, Europe, and the rest of the world.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.

Tags: